Singh, Janharpreet
Gsteiger, Sandro
Wheaton, Lorna
Riley, Richard D.
Abrams, Keith R.
Gillies, Clare L.
Bujkiewicz, Sylwia
Funding for this research was provided by:
National Institute for Health Research (NIHR300190, RM-FI-2017-08-027)
Medical Research Council (MR/R025223/1, MR/R025223/1)
Article History
Received: 24 December 2021
Accepted: 23 May 2022
First Online: 11 July 2022
Declarations
:
: Not applicable.
: Not applicable.
: JS, SG, LW, RDR, and CG do not have conflict of interest. SB has served as a paid consultant providing methodological advice to NICE, Roche and RTI Health Solutions, has received payments for educational events from Roche, and has received research funding from European Federation of Pharmaceutical Industries & Associations (EFPIA) and Johnson & Johnson. KRA has served as a paid consultant, providing methodological advice, to; Abbvie, Amaris, Allergan, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Creativ-Ceutical, GSK, ICON/Oxford Outcomes, Ipsen, Janssen, Eli Lilly, Merck, NICE, Novartis, NovoNordisk, Pfizer, PRMA, Roche and Takeda, and has received research funding from Association of the British Pharmaceutical Industry (ABPI), European Federation of Pharmaceutical Industries & Associations (EFPIA), Pfizer, Sanofi and Swiss Precision Diagnostics. He is a Partner and Director of Visible Analytics Limited, a healthcare consultancy company.